Reduced-Fluence Photodynamic Therapy for Central Serous Chorioretinopathy(CSC) and Multifocal Posterior Pigment Epitheliopathy(MPPE)

Reduced-Fluence Photodynamic Therapy for Central Serous Chorioretinopathy(CSC) and Multifocal Posterior Pigment Epitheliopathy(MPPE) - RFPDT for CSC and MPPE

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015283

Enrollment

Registered

2014-09-29

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy(CSC) and Multifocal Posterior Pigment Epitheliopathy(MPPE)

Interventions

Reduced Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of Chronic Central Serous Chorioretinopathy for more than 3 months.

Exclusion criteria

Exclusion criteria: Other associated ocular disease that compromised visual acuity Inability to obtain photographs Significant general disease such as diabetes, liver disease Porphyria

Design outcomes

Primary

Measure	Time frame
A reduction change of macular exudative retinal detachment after treatment	—

Countries

Japan

Contacts

Public ContactYusuke Shiode

Okayama University Hospital Department of Ophthalmology

shiode2001@yahoo.co.jp086-223-7151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026